Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial.

scientific article

Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/S1470-2045(12)70566-1
P698PubMed publication ID23312888

P50authorTadeusz PieńkowskiQ38290512
P2093author name stringChristoph Zielinski
Bella Kaufman
Istvan Lang
Diethelm Messinger
Richard Greil
Bohuslav Melichar
Salomon M Stemmer
Günther G Steger
Thomas Brodowicz
Zanete Zvirbule
Zsuzsanna Kahan
Semir Beslija
Central European Cooperative Oncology Group
Daniela Sirbu
Larisa Ryvo
P2860cites workOverall survival: patient outcome, therapeutic objective, clinical trial end point, or public health measure?Q44874881
RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancerQ44963911
Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancerQ47701435
A randomized phase II study of paclitaxel and bevacizumab with and without gemcitabine as first-line treatment for metastatic breast cancerQ48636986
Non-inferiority trials in breast and non-small cell lung cancer: choice of non-inferiority margins and other statistical aspects.Q53105911
Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upQ59567521
Progress against solid tumors in danger: the metastatic breast cancer exampleQ59616684
First-line therapy with moderate dose capecitabine in metastatic breast cancer is safe and active: Results of the MONICA trialQ33391647
Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancerQ33561160
Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancerQ34022546
Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled studyQ34172753
Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: a phase III, randomized, open-label trialQ36197026
Optimising the dose of capecitabine in metastatic breast cancer: confused, clarified or confirmed?Q37717833
1st International consensus guidelines for advanced breast cancer (ABC 1).Q37994463
P433issue2
P921main subjectbevacizumabQ413299
capecitabineQ420207
paclitaxelQ423762
metastatic breast cancerQ12859063
phase III clinical trialQ42824827
P304page(s)125-133
P577publication date2013-01-10
P1433published inLancet Oncology CommissionQ13747613
P1476titleBevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial.
P478volume14